Reset Pharma

4:15 PM - 4:30 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
Clinical Stage Neuro Biotechnology company bringing science to Psilocybin to help people raise above a life altering diagnosis. Initial focus is on patients with cancer suffering form Demoralization Syndrome.

Submitting IND this summer and moving directly to Ph2b study. In parallel, developing proprietary, commercially differentiated formulation to ensure competitive differentiation and protection.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Placeholder Photo
President and CEO
Reset Pharma